Hint mode is switched on Switch off
For swift navigation between sections

USANA Health Sciences
LEI 549300YTURXE814MAH96

PDF download

Choose all Reset all
Download Cancel
Organization name
USANA Health Sciences, Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Awards

News

15/04/2026 USANA Schedules First Quarter 2026 Earnings Release and Conference Call
11/02/2026 USANA Health Sciences: That Jim Brown Stepped Down As The Company’s Chief Executive Officer And President, And That Kevin Guest, The Company’s Chairman Of The Board, Reassumed The Role Of Chief Executive Officer. At The Time Of The Initial 8k, The Compensation Committee Of The Board (the “compensation Committee”) Had Not Determined The Compensation Arrangements For Mr. Brown Or Mr. Guest. The Compensation Committee Has Now Determined These Arrangements And, In Accordance With Instruction 2 To Item 5.02 Of Form 8k, The Company Is Filing This Amendment No. 1 To (i) Disclose The Material Terms Of The Transition Agreement Entered Into Between The Company And Mr. Brown And File Such Agreement As An Exhibit Hereto, And (ii) To Disclose The Material Terms Of Mr. Guest’s Compensation In Connection With His Appointment As Chief Executive Officer. Except As Specifically Set Forth Herein, No Other Changes Are Being Made To The Initial Form 8k, Financial Statements And Exhibits
12/01/2026 USANA Health Sciences Provides Preliminary Fiscal Year 2025 Net Sales and Issues Initial Fiscal Year 2026 Net Sales Outlook
08/01/2026 USANA Health Sciences: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Regulation Fd Disclosure, Financial Statements And Exhibits
20/10/2025 USANA Updates the Timing of the Release of Third Quarter 2025 Earnings Release and Conference Call
All organization news

Documentation

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
II q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • LEI
    549300YTURXE814MAH96
  • SIC
    2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
  • CIK
    0000896264
  • EIN
    87-0500306
Registration is required to get access.